Form 4: Cumberland Pharmaceuticals Director Caroline Young Acquires Shares Through 10b5-1 Trading Plan

Director Caroline Young of Cumberland Pharmaceuticals has acquired additional shares of common stock through a pre-arranged 10b5-1 trading plan.

Summary

• Caroline Young, a director at Cumberland Pharmaceuticals, has been purchasing shares of the company's common stock.
• These purchases were made automatically under a pre-arranged Rule 10b5-1 trading plan.
• The transactions occurred between December 2, 2024, and December 20, 2024.
• The number of shares purchased varied each day, ranging from 2 to 15 shares.
• The purchase prices ranged from $1.20 to $2.48 per share.
• Following these transactions, Ms. Young's total direct holdings increased to 29,818 shares.

Sentiment

Score: 6

Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither particularly positive nor negative. The director's purchases could be seen as a slightly positive sign of confidence.

Positives

• The director's purchases indicate confidence in the company's future.
• The use of a 10b5-1 plan suggests a structured and pre-planned approach to trading.

Industry Context

This is a routine filing related to insider trading activity, which is common for publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US.
• The use of a 10b5-1 trading plan is a common method for insiders to buy or sell shares without being accused of trading on non-public information.
• Many directors and officers at similar companies such as Teva Pharmaceuticals, Mylan, and Perrigo use similar plans.

Stakeholder Impact

• The share purchases may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Cumberland Pharmaceuticals, insider trading, Form 4, share acquisition, Rule 10b5-1, Caroline Young, director